ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
14 May 2020 - 10:42PM
ImmuCell Corporation (Nasdaq: ICCC) (the
“Company” or “ImmuCell”), a growing animal health company that
develops, manufactures and markets scientifically-proven and
practical products that improve the health and productivity of
dairy and beef calves, today announced a change in the
location of its 2020 Annual Meeting of Stockholders. In light of
the COVID-19 pandemic and in an effort to protect the health and
safety of the Company’s stockholders, employees and communities,
the Annual Meeting will be held by remote communication in the form
of both a dial-in conference call and an audio webcast rather than
an in-person event.
The Annual Meeting will take place Wednesday, June 10, 2020, at
3:00 PM ET, as previously announced. Stockholders of record of the
Company’s common stock at the close of business on Tuesday, April
14, 2020, are invited to participate in the Annual Meeting by
dialing 844-855-9502. Dial-in participants will have access to the
Question and Answer session that will take place after the formal
business of the meeting is concluded and after a review of its
Corporate Presentation slide deck, which is available now on the
Company’s website. The Company will also provide access to the
Annual Meeting via an “audio webcast” that can be accessed at:
https://www.webcaster4.com/Webcast/Page/1214/34878. Audio webcast
participants will not have the ability to ask questions during the
Question and Answer session.
Stockholders, regardless of their plans to attend the
virtual-only meeting, are encouraged to vote and submit their
proxies in advance of the Annual Meeting using one of the methods
described in the proxy materials. Stockholders may continue to use
the voting instruction form or proxy card provided, and no
additional action is required to be taken by stockholders who have
already submitted their proxy. Stockholders that would like to vote
at the Annual Meeting (instead of by proxy) should contact the
Company (Beth Toothaker at (207) 878-2770 Ext. 3103 or
btoothaker@immucell.com) to arrange for voting during the
meeting.
For more information about the Annual Meeting, including the
matters to be voted on during the Annual Meeting, please see the
Company’s Notice of Annual Meeting of Stockholders and its Proxy
Statement, which are available, along with the 2019 Annual Report
on Form 10-K, at
www.immucell.com. Conference
Call: Interested parties can access a conference call
scheduled by the Company to review the first quarter 2020 financial
results by dialing (844) 855-9502 (toll free) or (412) 317-5499
(international) at 9:00 AM ET on Thursday, May 14, 2020. A
teleconference replay of the call will be available for seven days
at (877) 344-7529 (toll free) or (412) 317-0088 (international),
utilizing confirmation #10143957. Investors are encouraged to
review the Company’s Form 10-Q for the three-month period ended
March 31, 2020 that will be filed with the SEC after the market
closes on May 13, 2020 and its updated Corporate Presentation slide
deck that provides an overview of the Company’s business and is
available under the “Investors” tab of the Company’s website at
www.immucell.com, or by request to the Company.
About ImmuCell: ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create
scientifically-proven and practical products that improve the
health and productivity of dairy and beef calves. ImmuCell
manufactures and markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain™, a novel treatment for subclinical
mastitis without a milk discard requirement that provides an
alternative to traditional antibiotics. Press releases and other
information about the Company are available at:
http://www.immucell.com.
Cautionary Note Regarding Forward-Looking Statements
(Safe Harbor Statement):This Press Release contains
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited
to, any statements relating to: our plans and strategies for our
business; projections of future financial or operational
performance; the timing and outcome of pending or anticipated
applications for regulatory approvals; factors that may affect the
dairy and beef industries and future demand for our products; the
extent, nature and duration of the COVID-19 pandemic and its
consequences, and their direct and indirect impacts on the
Company’s production activities, operating results and financial
condition and on the customers and markets the Company serves; the
scope and timing of ongoing and future product development work and
commercialization of our products; future costs of product
development efforts; the estimated prevalence rate of subclinical
mastitis and dairy producers’ level of interest in treating
subclinical mastitis given current economic and market conditions;
the expected efficacy of new products; estimates about the market
size for our products; future market share of and revenue generated
by current products and products still in development; our ability
to increase production output and reduce costs of goods sold
associated with our new product, Tri-Shield
First Defense®; the future adequacy of our own
manufacturing facilities or those of third parties with which we
have contractual relationships to meet demand for our products on a
timely basis; the anticipated costs of (or time to complete)
planned expansions of our manufacturing facilities and the adequacy
of our funds available for these projects; the continuing
availability to us on reasonable terms of third-party providers of
critical products or services; the robustness of our manufacturing
processes and related technical issues; estimates about our
production capacity, efficiency and yield; the future adequacy of
our working capital and the availability and cost of third-party
financing; future regulatory requirements relating to our products;
future expense ratios and margins; future compliance with bank debt
covenants; costs associated with sustaining compliance with current
Good Manufacturing Practice (cGMP) regulations in our current
operations and attaining such compliance for the facility to
produce the Nisin Drug Substance; implementation of international
trade tariffs that could reduce the export of dairy products, which
could in turn weaken the price received by our customers for their
products; our effectiveness in competing against competitors within
both our existing and our anticipated product markets; the
cost-effectiveness of additional sales and marketing expenditures
and resources; anticipated changes in our manufacturing
capabilities and efficiencies; the value of our net deferred tax
assets; projections about depreciation expense and its impact on
income for book and tax return purposes; anticipated market
conditions; and any other statements that are not historical facts.
Forward-looking statements can be identified by the use of words
such as “expects”, “may”, “anticipates”, “aims”, “intends”,
“would”, “could”, “should”, “will”, “plans”, “believes”,
“estimates”, “targets”, “projects”, “forecasts”, “seeks” and
similar words and expressions. In addition, there can be no
assurance that future developments affecting us will be those that
we anticipate. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to difficulties or delays in development, testing,
regulatory approval, production and marketing of our products
(including the First Defense® product line and
Re-Tain™), competition within our anticipated
product markets, customer acceptance of our new and existing
products, product performance, alignment between our manufacturing
resources and product demand, our reliance upon third parties for
financial support, products and services, changes in laws and
regulations, decision making and delays by regulatory authorities,
currency values and fluctuations and other risks detailed from time
to time in filings we make with the SEC, including our Quarterly
Reports on Form 10-Q, our Annual Reports on Form 10-K and our
Current Reports on Form 8-K. Such statements involve risks and
uncertainties and are based on our current expectations, but actual
results may differ materially due to various factors, including the
risk factors summarized above.
Contacts: |
Michael F. Brigham, President and CEO |
|
ImmuCell Corporation |
|
(207) 878-2770 |
|
|
|
Joe Diaz, Robert Blum and Joe Dorame |
|
Lytham Partners, LLC |
|
(602) 889-9700 |
|
iccc@lythampartners.com |
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2024 to May 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From May 2023 to May 2024